title: Atypical antipsychotics and cardiovascular risk in schizophrenic patients.
authors.forename: R H
authors.initials: RH
authors.lastname: Bouchard
authors.forename: M F
authors.initials: MF
authors.lastname: Demers
authors.forename: I
authors.initials: I
authors.lastname: Simoneau
authors.forename: N
authors.initials: N
authors.lastname: Alméras
authors.forename: J
authors.initials: J
authors.lastname: Villeneuve
authors.forename: J P
authors.initials: JP
authors.lastname: Mottard
authors.forename: C
authors.initials: C
authors.lastname: Cadrin
authors.forename: I
authors.initials: I
authors.lastname: Lemieux
authors.forename: J P
authors.initials: JP
authors.lastname: Després
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001569:Benzodiazepines; D001835:Body Weight / Q000187:drug effects; D002318:Cardiovascular Diseases / Q000139:chemically induced*; D003430:Cross-Sectional Studies; D006801:Humans; D008297:Male; D000077152:Olanzapine; D010890:Pirenzepine / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012307:Risk Factors; D018967:Risperidone / Q000009:adverse effects* / Q000627:therapeutic use; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy*
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D010890:Pirenzepine; D018967:Risperidone; D000077152:Olanzapine